TUBB2B

Tubulin beta-2B chain · Q9BVA1 · TUBB2B on Sugi Atlas →

132,530 patent compounds predicted against TUBB2B, 83,760 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Curacin A Curacin A (SCHEMBL61304) 1.00 20/20
Vintriptol Vintriptol (SCHEMBL93959) 1.00 15/20
Vindesine Vindesine (SCHEMBL4420) 0.85 13/20
Vindesine Vindesine (SCHEMBL4421) 0.85 13/20
Vindesine Vindesine (SCHEMBL4285) 0.85 12/20
SCHEMBL147173 SCHEMBL147173 0.50 12/20
SCHEMBL147174 SCHEMBL147174 0.50 12/20
Combretastatin Combretastatin (SCHEMBL19955) 1.00 9/20
Combretastatin Combretastatin (SCHEMBL19956) 1.00 9/20
SCHEMBL118593 SCHEMBL118593 0.69 9/20
Centaureidin Centaureidin (SCHEMBL9953) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43160) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43161) 1.00 8/20
SCHEMBL68067 SCHEMBL68067 0.62 8/20
Fosbretabulin Fosbretabulin (SCHEMBL66079) 0.61 8/20
Vinorelbine Vinorelbine (SCHEMBL4765) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18945) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18946) 1.00 7/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 7/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 7/20

Clinical trials — most relevant to TUBB2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer PHASE3COMPLETED
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients PHASE2ACTIVE_NOT_RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis PHASE1/PHASE2WITHDRAWN
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Mapping Disease Pathways for Biliary Atresia nanRECRUITING
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method) nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia nanCOMPLETED
Myotubular Myopathy Genetic Testing Study nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
WGS of Korean Idiopathic Bronchiectasis nanUNKNOWN
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Differential Study of Muscle Transcriptome nanCOMPLETED
Identification of Viable Human Embryos Using Three Different Methods nanCOMPLETED
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TUBB2B binder may also engage these)

ProteinNameSimilarity
Q6B856 1.000 Q6B856 →
TUBB2A Tubulin beta-2A chain 1.000 landscape →
P85108 1.000 P85108 →
P69893 1.000 P69893 →
P11833 1.000 P11833 →
Q27U48 1.000 Q27U48 →
Q6GLE7 1.000 Q6GLE7 →
O44388 1.000 O44388 →
Q3MHM5 1.000 Q3MHM5 →
P68372 1.000 P68372 →
P46265 1.000 P46265 →
P32882 1.000 P32882 →
Q2HJ81 1.000 Q2HJ81 →
P12456 1.000 P12456 →
P09203 1.000 P09203 →
Q4R4X8 1.000 Q4R4X8 →
O59837 1.000 O59837 →
P02554 1.000 P02554 →
P30883 1.000 P30883 →
P61858 1.000 P61858 →
Q9NFZ7 1.000 Q9NFZ7 →
P41937 1.000 P41937 →
Q24560 1.000 Q24560 →
P33127 1.000 P33127 →
Q4R5B3 1.000 Q4R5B3 →
P14140 1.000 P14140 →
Q767L7 1.000 Q767L7 →
Q2KJD0 1.000 Q2KJD0 →
P09244 1.000 P09244 →
P69895 1.000 P69895 →